Abstract：Objective: To study the clinical efficacy of loratadine combined with azelastine nasal spray in the treatment of allergic rhinitis. Methods: 243 patients with allergic rhinitis were enrolled in our hospital from February 2015 to January 2017. All patients were divided into control group (n=119) and study group (n=124) according to the random number table method. The patients in the control group were treated with azelastine nasal spray. The patients in the study group were treated with desloratadine and azelastine nasal spray, and the IL-4, IL-6, IL-10 and other inflammations were compared between the two groups before and after treatment. Factor levels, VCAM-1, IgE levels before and after treatment, symptom scores before and after treatment, and clinical efficacy after treatment. Results: There was no significant difference in the levels of IL-4, IL-6 and IL-10 before treatment between the two groups (P>0.05). The levels of IL-4, IL-6 and IL-10 were significantly lower in the study group than in the control group after treatment. Group, and two groups of patients after treatment significantly lower than their respective treatment, and were statistically significant (P<0.05). There was no significant difference in the levels of VCAM-1 and IgE between the two groups before treatment (P>0.05). The levels of VCAM-1 and IgE in the study group were significantly lower than those in the control group after treatment, and the two groups were significantly lower than the respective treatment after treatment. Before and with statistical differences (P<0.05). There was no significant difference in symptom scores before treatment between the two groups in terms of nasal itching, nasal congestion, runny nose, and sneezing (P>0.05). Symptom scores after treatment in the study group were significantly lower than those in the control group, and both groups were significantly lower after treatment. Before each treatment, there was a statistical difference (P<0.05). The total effective rate of the control group was 79.83%; the total effective rate of the study group was 96.77%. There was a statistically significant difference in the total effective rate between the two groups (P<0.05). The incidence of adverse reactions in the control group was 3.36%; the incidence of adverse reactions in the study group was 4.03%. Adverse reactions resolved spontaneously after the end of treatment, and no abnormalities of kidney, liver and heart function were seen. Conclusion: Desloratadine combined with azelastine nasal spray can reduce inflammatory reactions, reduce serum inflammatory factors, VCAM-1 and IgE levels, significantly improve clinical symptoms, improve treatment efficiency, and have good therapeutic effect.
朱丹. 过敏性鼻炎治疗中地氯雷他定联合氮卓斯汀鼻喷剂的临床疗效及安全性分析[J]. 河北医学, 2018, 24(10): 1727-1730.
ZHU Dan. Clinical Efficacy and Safety Analysis of Loratadine and Azelastine Nasal Spray in the treatment of Allergic Rhinitis. HeBei Med, 2018, 24(10): 1727-1730.
[1] 李琪,袁伟,白杨.地氯雷他定治疗过敏性鼻炎的安全性与有效性分析[J].西南国防医药,2013,23(2):141~143. [2] 邱剑波.氯雷他定联合布地奈德喷剂治疗过敏性鼻炎34例的疗效评价[J].中国药业,2013,22(11):22~23. [3] 张德斌.针刺联合雷火灸治疗过敏性鼻炎27例[J].陕西中医,2014,35(5):593~594. [4] 吴亚庆,廖建春.过敏性鼻炎患者血清白细胞介素,微量元素及黏附分子的变化规律研究[J].中国医师进修杂志,2013,36(33):17~20. [5] 刘维,张应龙.咪唑斯汀对过敏性鼻炎患者血清微量元素及特异性免疫球蛋白E、嗜酸性粒细胞阳离子蛋白、炎性因子的影响观察[J].中国医药导报,2013,10(7):99~101. [6] Jie Q,Kodithuwakku ND,Yuan X,et al.Anti-allergic and anti-inflammatory properties of a potent histamine H1 receptor antagonist,desloratadine citrate disodium injection,and its anti-inflmmatory mechanism on EA.hy926 endothelial cells[J].Eur Pharmacol,2015,754(4):1~10. [7] Chen ML,Xu SH,Zhou PP,et al.Desloratadine citrate disodium injection,a potent histamine H-1 receptor antagonist,inhibits chemokine production in ovalbumin-induced allergic rhinitis Guinea pig model and histamin-induced human nasal epithelial cells via inhibiting the ERK1/2 and NF-kappa B signal cascades[J].Eur Pharmacol,2015,767(1):98~107. [8] 凌云,杨春悦,杨红梅.氮卓斯汀鼻喷剂联合地氯雷他定治疗过敏性鼻炎65例的疗效评价[J].中国免疫学杂志,2014,30(6):828~830. [9] 张治成,杨晓,杨晓刚.意守式针灸疗法联合枸地氯雷他定治疗中重度间歇性过敏性鼻炎临床疗效及预后分析[J].重庆医学,2016,45(25):3542~3544.
2018, Vol. 24 
冀公网安备13080202000677号